Introduction
Diabetic neuropathy is a common complication of diabetes but the mechanisms underlying its pathogenesis have historically received less attention when compared to the renal, eye, and macrovascular lesions which are also frequently present. The recognition of the high prevalence of neuropathy which was found to be present in 39 % of healthy insulin-dependent diabetic patients in the Diabetes Control and Complications Trial (DCCT)' and has been reported to afflict over 50 % of diabetic subjects after 25 years of diabetes2 or 44 % of diabetic subjects between 70 and 79 years of age3 and its major contribution to sepsis, debility, and lower limb amputations4 has stimulated research into its pathogenesis. These studies have provided clues which suggest that many of the mechanisms underlying its pathogenesis may in fact be linked. Thus although the diabetic state undoubtedly leads to a spectrum of abnormalities which lead to the characteristic findings of nerve fibre atrophy and the exciting possibility arises that therapeutic intervention to correct one hyperglycaemia-induced Correspondence to: Dr M.1. Stevens Although the cause of diabetic neuropathy remains unknown its correlation with the degree and duration of the antecedent h y p e r g l y~a e m i a~,~ implicates a pathogenesis directly precipitated by the diabetic state. In the DCCT, for example, intensive insulin therapy reduced the appearance of neuropathy at 5 years by up to 69 %. 9 The resultant effects of the prevailing hyperglycaemia or insulin deficiency precipitating both m e t a b~l i c~~'~~' ' and vascular defects12-15 in the nerve are highly controversial as is the precise tissue compartment in which these perturbations primarily occur, The principle metabolic defects which have been implicated include disruption of the polyol or sorbitol pathway, abnormalities in lipid metabolism, advanced glycosylated end-product formation, increased oxidative damage, and diabetesinduced defects in growth factors. The factors which may contribute to nerve ischaemia include structural defects in the endoneurial microvasculature together with rheological abnormalities, and abnormalities in vasoactive agents which play a key role in the control of nerve blood flow including the endothelium-derived relaxing factor, nitric oxide and the eicosanoids. It is also unclear whether these diabetes-induced perturbations primarily affect peripheral nerve neurons or the Schwann DIABETIC MEDICINE, 1995; 12: 566-579 DTT7 REVIEW cells, the perineurial or extracellular matrix, the endoneurial vasculature, or perhaps a site remote from the peripheral nerve such as the autonomic ganglia. This review will focus on the current hypotheses which have been invoked in the pathogenesis of diabetic neuropathy and also evaluate whether they are as divergent as first seems apparent.
Aldose Reductase, The Polyol Pathway, and the Myoinositol Depletion Hypothesis
Considerable evidence implicates involvement of the polyol pathway in which glucose is metabolized to sorbitol and fructose by the enzymes aldose reductase (AR2) and sorbitol dehydrogenase, respe~tively,~,~,'~,' 1,16-18 in the development of diabetic neuropathy. Glucose-induced alterations in the metabolism of sorbitol, myo-inositol (a precursor for phosphoinositide (PI) ~y n t h e s i s )~,~, '~, '~, '~ and taurine (a p-amino acid)19 and their associated effects on PI and calcium metabolism have been proposed to be the mechanisms whereby high polyol pathway activity precipitates its deleterious effects.
The myo-inositol depletion hypothesis20-22 has for many years been extensively evaluated as the primary polyol-pathway-related defect underlying acute experimental nerve conduction velocity (NCV) slowing. In diabetic rat peripheral nerve the metabolism of glucose via the high K , AR2 promotes sorbitol and fructose accumulation, and myo-inositol depletion, which has been implicated in slowing of nerve c o n d~c t i o n .~~-~~ myo-lnositol supplementation or aldose reductase inhibitors (ARls) normalize nerve myo-inositol and nerve conduction velocity (NCV).23,27-32 Th us the action of ARls on the acute and rapidly reversible slowing of nerve conduction in experimental diabetes is thought to be mediated in part by correction of underlying polyolpathway-induced abnormalities in nerve myo-inositol metabolism.26 Depletion of nerve myo-inositol has been proposed to impair incorporation into a class of membrane phospholipids, the phosphoin~sitides.~~' o,' Impaired activation of protein kinase C (PKC) by PIderived diacylglycerol (DAG) may be the link between altered myo-inositol metabolism and (Na, K)-ATPase regulation in diabetic nerve as a reduction in arachidonylcontaining DAGs and PKC activity has been demonstrated in diabetic rat sciatic nerve.33 Moreover exogenous PKC agonists correct impaired nerve ouabain-sensitive energy metabolism and ATPase activity in ~i t r o .~~,~~ Therefore the effect of myo-inositol depletion on (Na,K)-ATPase activity may be mediated through altered PI turnover and a PKC-dependent mechanism in experimental diabetes.36 However, in some diabetic tissues with low polyol pathway activity, glucose may lead to increased de novo synthesis of DAG and PKC a~t i v a t i o n~~,~~ which mediates a reduction in (Na,K)-ATPase a~t i v i t y .~" Therefore PKC activation may either have bi-directional effects on (Na,K)-ATPase activity or chronic Stimulation of PKC could potentially lead to compensatory up-or downregulation of its action. Thus it would appear that in tissues with high AR2 activity (such as rat nerve) DAG depletion is the predominant response to hyperglycaemia contrasting with tissues with relatively lower aldose reductase activity (such as retinal capillary endothelium) where DAG accumulation predominates. The application of the myo-inositol depletion hypothesis to human nerve remains controversial as although ARls diminish sorbitol accumulation and also increase nerve conduction, nerve myo-inositol is not measurably a I tered40-42 and (Na,K)-ATPase has to date not been assessed.
The (Na,K)-ATPase and Nerve Conduction
The nerve (Na,K)-ATPase is responsible for the maintenance of the transmembrane ionic gradient which is necessary to facilitate the conduction of electrical impulses. Perturbations in nerve (Na,K)-ATPase emerged as a possible common denominator for altered energy metabolism,2o nerve conduction slowing, and structural abnormalities in acute experimental diabetes based on direct measurement of reduced nerve (Na,K)-ATPase activity in its correction by myo-inositol ~upplementation,~~ ARI treatment25,45 or prostacyclin analogues. 46 Moreover pharmacological manipulation of non-diabetic rats with agents which impaired the nerve (Na,K)-ATPase were able to reproduce diabetic nerve conduction s l~w i n g .~' ,~~ Thus the ability to restore normal nerve (Na,K)-ATPase activity and also correct NCV has remained central to the metabolic hypothesis of diabetic neuropathy but the mechanism(s) by which diabetes results in its impairment remain controversial.
Osmotic Dysregulation and the Compatible Osmolyte Hypothesis
For over 20 years, stimulation of AR2 activity by mass action has been viewed as a critical link between hyperglycaemia and the tissue damage underlying some chronic diabetic compli~ations.~"~' The view that AR2 is an important physiological intracellular osmoregulator in the renal medulla, where it is induced by extracellular hyperosmolality, has recently emerged as part of a 'compatible osmolyte' h y p o t h e s i~.~' -~~ This hypothesis argues that non-ionic and therefore, 'n~n-perturbing'~~ compounds such as sorbitol, myo-inositol, and taurine, function as alternative organic intracellular osmolytes responding coordinately to changes in external osmolality, thereby buffering injurious shifts in the intracellular electrolyte and water c o m p o s i t i~n .~~-~~ Osmolar stress precipitates compensatory alterations in the intracellular concentration of these alternative osmolytes by induction or suppression of the relevant synthetic enzymes (AR2 in the case of sorbitolS5) or membrane transporters (the sod i urn-myo-i nositol, and taurine transporter^)^^,^^, thus accumulating or disposing
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of these osmolytes in a coordinated fashion. Although initially regarded as metabolically inert, these osmolytes are now thought to have important metabolic as well as osmoregulatory roles.5,50,51,54,58-60 Thus myo-inositol may become limiting for PI signalling,59 and taurine depletion may lead to disruption of intracellular calcium homeostasis, 6o neuronal hyperexcitabi I ity, ' and defects of neurotransmitter release and ion c o n d~c t a n c e . " ,~~ Given the osmoregulatory and metabolic importance of taurine and myo-inositol, abnormal expression of the osmo-responsive genes that modulate compatible osmolyte metabolism might exaggerate the deleterious effects of otherwise trivial osmolar and/or metabolic stress, such as might occur in diabetes mellitus, thereby predisposing to the development of diabetic neuropathy. Indeed, provocative, fragmentary but conflicting data suggest a possible association between increased AR2 enzymatic activity and/or protein and the presence of late diabetic compl ications. 64-66
Disturbances in Cellular Redox
Increased flux through AR2 and sorbitol dehydrogenase oxidizes the NADPH/NADP+ and reduces the NADHi NAD' redox couples, respectively, thereby perturbing other adenine nucleotide-linked reactions. Therefore activation of the polyol pathway in diabetes may lead to metabolic defects by mechanisms involving osmotic perturbations as considered above, or by redox disturbances (Figure 1 ). Increased oxidative tissue damage in diabetes has been proposed to result from oxidation of the NADPH/NADP+ couple through depletion of reduced glutathione, although direct supporting evidence is lacking.67 Depletion of NADPH may also affect the synthesis of the potent vasodilator and neuromodulator nitric oxide (NO) as both nitric oxide synthase (NOS) and AR2 utilize NADPH as a cofactor. Thus potentially consumption of NADPH by AR2 may lead to NO depletion with secondary effects on nerve blood flow (and nerve Na/KATPase (considered below). 
Nerve lschaemia in Diabetes
There is now increasing evidence that nerve ischaemia plays a central role in the pathogenesis of diabetic neuropathy. Studies in anaesthetized rats have identified reduced endoneurial blood flow and oxygen tension, and increased endoneurial vascular resistance after 4 months of streptozotocin d i a b e t e~.~~,~~ A 40 % reduction in nerve blood flow has been observed as early as 1 week after the induction of diabetes in the rat.13 Not all investigators agree with the concept of an early reduction in nerve blood flow in experimental diabetes, as microsphere experiments in acutely diabetic rats have suggested increased blood flow and vascular permeability.7' Support for a leading role of a reduction of nerve blood flow early in diabetes in the development of NCV slowing i s provided by the ability of vasodilatory agents to partially or completely correct nerve conduction ~l o w i n g . '~, ' For example, the alpha-adrenergic receptor inhibitor prazosin prevented slowing of conduction in the tibia1 motor and saphenous sensory nerves in acutely streptozotocin-diabetic rats14 and the angiotensin converting enzyme inhibitor lisinopril has been found to prevent 75 % of the slowing of sciatic motor and sensory NCV after 2 months of d i a b e t e~. '~ Lisinopril treatment also increased sciatic nerve capillary density, leading to the conclusion that lisinopril treatment reduced peripheral vascular resistance and increased nerve blood flow by stimulating angiogenesis. The nature of the underlying pathology leading to reduced nerve blood flow remains, however, the subject of controversy.
The concept of nerve ischaemia in diabetes is however not new: Fagerberg's early autopsy studies demonstrated thickened endoneurial vessel walls, which stained paminosalicylic acid positive and occluded endoneurial microvessels.'L A hypoxic hypothesis states that chronic experimental diabetic neuropathy, which is analogous to human diabetic neuropathy, is the result of initial damage to the nerve microvessels, with resultant nerve fibre degeneration secondary to endoneurial h y p o~i a .~' Suggested clinical evidence in support of nerve hypoxia in the development of neuropathy has been the finding of a reduction of endoneurial oxygen in the sural nerves of diabetic patients with p~l y n e u r o p a t h y~~ and the Dm REVIEW development of abnormalities of neural conduction in people with hypoxia secondary to chronic obstructive airway d i~e a s e .~~,~~ Non-diabetic animals exposed to chronic hypoxia, show some impairment of NCV, and resistance to ischaemic conduction block, abnormalities of which are reversible when the hypoxia is corrected76 and experimentally-induced reduction in caudal nerve action potential can be normalized by hyperbaric oxygenation, but without improvement in NCV.77 Thus although hypoxia may play a role in the development of diabetic neuropathy, this may not to be the sole factor.
An understanding of both the anatomy of the nerve vasculature as well as the local (i.e. vasoactive agents) and distant (sympathetic tone) factors which regulate nerve blood flow may help elucidate the pathogenetic mechanisms which contribute to ischaemia. The vascular supply of nerve is provided by both an intrinsic system consisting of microvessels which are situated longitudinally within the fascicular endoneurium and an extrinsic system composed of the larger nutritive arteries, arterioles, venules, and epineural vessels. The nerve has only a very limited capacity to autoregulate its vascular supply: perhaps only the epineural and perineural vessels are capable of autoregulation, thus alterations in systemic pressure lead to passive fluctuations of perfusion in the n e r~e .~~,~~ Extensive anastomoses (both arteriovenous and arterioarterial) are formed between the two systems by the epi-and perineural vessels, which together with the low metabolic requirements of the nerve confer a resistance to ischaemic insult^.^' However, the recent demonstration of extensive perineurial AV anastomoses in subjects with diabetic neuropathy has led to speculation regarding the role of a 'vascular steal phenomenon' occurring, in which the nutritive endoneurial capillary flow is impaired by the high shunt flow.ao A number of vascular endoneurial abnormalities have been found in diabetes which have been suggested to implicate ischaemia as the primary pathogenetic defect leading to neuropathy. Defects identified include basement membrane thickening and duplication, endothelial cell swelling and proliferation, intimal and smooth muscle cell proliferation, capillary closure, and furthermore vessels from autopsy specimens of sural nerve have been found to be occluded by platelet t h r~m b i .~~, " -~~ The interpretation of both the cause and the effects of these histological observations is not, however, straightforward as other studies have failed to find evidence of increased frequency of endothelial cell abnormalities in sural nerves of neuropathic diabetic patients8' and suggested that differences in age may be responsible for the differences observed by other investigators. Furthermore, the non-uniform loss of myelinated fibres in diabetic sural nerves in patients with polyneuropathy, which has been taken to indicate nerve ischaemia, was also found in patients with Type 1 hereditary motor and sensory neuropathy, which is not thought to have a vascular basis.88 Thus the interpretation of nerve vascular histological abnormalities in diabetic AETIOLOCY OF DIABETIC NEUROPATHY patients remains controversial. These difficulties do not however exclude a significant ischaemic component in the development of neuropathy which appears likely in view of the accumulating evidence from animal studies.
Rheological Abnormalities
The contribution of rheological abnormalities in diabetes to the pathogenesis of diabetic neuropathy remains uncertain. Potentially at least, diabetic patients may have an increased susceptibility to intravascular thrombosis as whole blood viscosity is i n~r e a s e d~~,~~ as is red cell aggregation and fibrinogen level^.^' One study which addressed the role of abnormal rheology in the pathogenesis of diabetic distal symmetrical neuropathy, failed to find a difference in rheological abnormalities in patients who developed neuropathy, compared to diabetic subjects without neuropathy.y2 The study did however confirm that blood viscosity was increased and red cell deformability was reduced in all the diabetic patients.
If there is a primary abnormality of the neuronal microvasculature, with resultant reduction in the luminal area, neural blood flow may be compromised by the abnormal rheology in the diabetic state, as vessel radius primarily determines blood flow.
Altered Synthesis, Release, and Sensitivity to Vasoactive Factors in Diabetes
The mechanisms underlying the decrease in nerve blood flow seen in experimental diabetic neuropathy are unknown but depletion of NOy3 or an imbalance of the thromboxane:prostacyclin ratio, leading to a predominance of vasoconstricting e i c~s a n o i d s ,~~ may potentially result in alterations in sympathetic tone and basal vascular tone with the net result of a reduction of endoneurial blood flow.
Nitric Oxide
Over the last few years the diverse biological functions of the endothelium-derived relaxing factor NO have become increasingly apparent. This highly reactive, short-lived radical gas has been shown to mediate vasodilatation and macrophage cytotoxicity, and to play an important role as a neuronal messenger within the CNS.93,9',96 Recently, its importance in the pathogenesis of diabetic complications, including diabetic neuropathy, has been the subject of increasing interest. Endoneurial endothel ial cells, smooth muscle cells, pericytes, and sympathetic ganglia are also most likely sites of nitric oxide synthase (NOS), the enzyme catalysing the conversion of 1-arginine to citrulline and NO.97 In the endothelium and neuron, NOS is calcium-calmodulin dependent and increases in intracellular calcium stimulate its activity." Locally released NO in the endoneurial microvasculature would, along with locally derived REVIEW D m prostacyclins, presumably exert a potent vasodilatory effect which modulates regional blood flow. Endothelium-. dependent relaxation of smooth muscle has been shown to be impaired in both human98 and experimentally induced diabete~.~~-'O' The mechanisms underlying this deficit are unclear but may involve depletion of N099-'05 or altered smooth-muscle sensitivty to N0.'06 Impaired local synthesis of NO may alter basal vascular tone either by reduced activation of soluble guanylate cyclase in vascular smooth or by decreased Na/K-ATPase'O' potentially resulting in decreased endoneurial blood flow. The impaired endoneurial vasodilatory responses to acetyl c h~l i n e~~, '~~ but preserved endothelial-independent vasodilatory responses to, for example, sodium nitroprusside,' O1 nitroglycerin, ' O0,' O2 and other agents which directly release NO, implicate a defect or defects in either endoneurial N O synthesis or release as the cause of impaired vascular responses in diabetes.
Alternatively, although local endoneurial NO depletion may directly contribute to decreased endoneurial blood flow, the potential of NO as an inhibitory neurotransmitter'l0 and its role in the maintenance of blood pressure via modulating sympathetic toney3 suggest another possible mechanism. The acute reduction in endoneurial blood flow in diabetes may be mediated by acutely increased sympathetic tone, as inhibition of basal sympathetic vascular tone by guanethidine restores both nerve blood flow and nerve conduction to normal levels in acute experimental d i a b e t e~. '~ If NO is functioning as an inhibitory neurotransmitter, it is tempting to speculate that postsynaptic neuronal NO might dampen presynaptic acetylcholine release thereby modulating peripheral sympathetic tone5 (Figure 2) . Thus in diabetes, if NO depletion at the level of the sympathetic ganglia is an early event, this may result in increased vasoconstricting sympathetic tone to the nerve vasculature precipitating nerve ischaemia and acute nerve conduction slowing.
Altered NO metabolism in diabetes may be the means by which the divergent metabolic and vascular hypotheses evoked in the pathogenesis of diabetic neuropathy are j~i n e d .~, " Metabolic competition for NADPH by AR2
and NOS has been proposed as a potential mechanism by which these hypotheses are linked5,47,111 (Figure 3) . AR2-mediated consumption of NADPH may not only directly impair the activity of NOS, but may also lead to increased levels of superoxide radicals, as NADPH is also required for the production of reduced glutathione."> The diabetic endothelium is abnormally sensitive to damage mediated by both increased production of superoxide radicals'02 which may also destroy N0,'02,'03 and to the increased formation of advanced glycosylation end products by glucose' l 2 and fructose. Support for metabolic competition between NOS and AR2 is provided by the fact that ARls not only restore osmolyte balance in the nerve5,10,19,2y,30 but also improve nerve blood flow.'l4 Moreover, in a 3-month STZ-D rat model ARI treatment has been demonstrated to restore endotheliumdependent relaxation to within normal limits.' l 1 Recently, an NOS inhibitor 1-nitro-N-methyl arginine ester (1-NAME) was found to reverse the beneficial effects of an ARI in acute experimental diabetic neuropathy, in spite of a significant decrease in nerve sorbitol and an increase in nerve myo-inositol levels. 1-NAME was also found to slow NCV and reduce Na/K-ATPase activity in chronically (3-month) treated non-diabetic animal^.^' These data support a role for NO in mediating, at least partially, the beneficial effects of ARls on nerve blood flow and NCV slowing and also a role in the maintenance of the nerve Na/K-ATPase, thus suggesting both a vascular and metabolic action. exert more distal effects on nerve function independently of nerve blood flow via direct effects on the nerve Na/ K-ATPase a c t i~i t y :~~, '~~ N O may modulate PI turnover"8 and thus act synergistically with osmotically-induced myo-inositol depletion in impairing signal transduction and NaiK-ATPase regulation.
N O S
Prostaglandin Metabolism
Diabetes-induced abnormalities in eicosanoid metabolism may potentially have wide-ranging effects on nerve function. In diabetes, an increase in the thromboxane: prostacyclin ratioy4 may contribute to nerve ischaemia (and reduced nerve Na/K-ATPase). Increases in vasoconstricting thromboxanes PGH2' l 9 Tx A2,I2' PGF2a, and reduction in vasodilating prostacyclin have been described in isolated diabetic vascular tissue.'*' Microvascular tone is dependent on the opposing actions of endothelial prostacyclin, which together with NO elicits vasodilatation, and thromboxane A2, which is found mainly in blood platelets and produces vasoconstriction.120 lschaemia in the nerve may activate phospholipase disrupting membrane phospholipids and generating prostag land i ns from activated arach idon ic acid'Z3 ( Figure 5 ). A hypoxic insult may also be one of the triggers for the production of the superoxide radical via the breakdown of ATP.69 The generation of lipid hydroperoxides by the action of free radicals may result in increased cyclooxygenase activity and a reduction in prostacyclin synthetase activity, thus increasing the thromboxane:prostacyclin ratio, with resultant vasoconstriction and platelet aggregation. Phospholipase activation may also generate endothelium disrupting leukotrienes. Eicosanoids may serve to limit the detrimen- Compelling evidence in the diabetic rat model implicates a role for disruption of prostaglandin metabolism in NCV slowing. Although nerve prostacyclin levels are typically not depleted early in experimental ne~ropathy,'~ altered prostaglandin metabolism at other sites may contribute to the early decrease in endoneurial blood flow as both PGE, and PGE2 inhibit sympathetic neurotransmission mainly by reducing the release of noradrenaline from adrenergic nerve terminal^.'^^,'^^ Reduced nerve prostacyclin has been found in chronic (+month) experimental diabetesg4 and prostaglandin El analogue administration has been shown to restore NCV to normal in diabetic rats."4 As levels of CAMP have been found to be reduced in experimental ne~ropathy'~' and there exists a direct correlation between nerve prostacyclin levels, CAMP,'*' and the Na/K-ATPase128 which are corrected by prostaglandin El administration, then the possibility arises that prostaglandin metabolism may be a key modulator of the both endoneurial blood flow and nerve Na/K-ATPase activity. Moreover therapeutic manipulations which have been shown to correct nerve conduction slowing such as myo-inositol supplementation or gamma-linolenic acid (GLA-from evening primrose oil)'6* '8,23,24,29,129 ,130 may in fact be working at least partly by increasing prostacyclin production as both may potentially increase arachidonic acid which is rate limiting for prostaglandin synthesis.
Carnitine Metabolism
Abnormalities in fatty acid metabolism have also been implicated in the pathogenesis of neuropathy as diabetesinduced defects in the desaturation of gamma-linoleic 5 72 acid to gamma-linolenic acid exist130*131 which may precipitate a reduction in nerve blood flow via a decrease in production of vasodilating eicosanoidsg4 ( Figure 5) and by the accumulation of toxic long chain fatty acids in the peripheral nerve.
Abnormal carnitine metabolism in diabetes may also predispose to the development of diabetic neuropathy. Carnitine and its acetyl ester acetyl 1-carnitine play a central role in fatty acid metabolism and are important in the production of the metabolic f~e l s . '~~, '~~ A reduction in plasma free carnitine and an increase in the carnitine esters has been found in d i a b e t e~'~~, '~~ and this may lead to the accumulation of long-chain fatty acids which can perturb membrane stability' 36 and f~n c t i o n '~' and disrupt energy production in the nerve. ' 38,1 39 Carnitine and acetyl 1-carnitine promote transport of cytosolic long-chain fatty acids across the inner mitochondria1 membrane to undergo p-oxidation and may thereby prevent their excessive accumulation.' 35-142 Acetyl I-carnitine may have neurotrophic properties as it facilitates the neurite outgrowth of rat phaeochromocytoma cells (PC12) to nerve growth factor'43 (NGF) and stimulates nerve growth factor receptor (NGFR) synthesis in PC12 cells by increasing NGFR protein and mRNA (1 44). Acetyl-1-carnitine also enhances nerve fibre repair and regeneration after nerve tran~ection'~' in non-diabetic rats and has cholinergic Polyol pathway-induced accumulation of NADH precipitating a metabolic 'pseudohypoxia' has also been implicated in tissue fatty acid accumu-I a t i~n ,~' , '~~ and may thus also be amenable to acetyl 1-carnitine treatment. Finally, acetyl-1-carnitine may affect arachidonic acid metabolism, enhancing the production of prostacyclin which may improve both nerve blood flow and correct reduced nerve Na/K-ATPase. Preliminary studies have suggested that acetyl 1-carnitine can prevent slowing of nerve conduction in streptozotocin-diabetic rat^'^^,'^' and vascular d y s f~n c t i o n '~~ although the mechanisms remain obscure. On-going phase 3 clinical studies are examining its potential in the management of early diabetic neuropathy.
Nonenzymat ic GI ycat ion
Nonenzymatic protein glycation' is a well-established mechanism by which glucose and its metabolites may exert detrimental effects in diabetes by a process which may be exacerbated by increased flux through the polyol pathway as fructose, and some of its triose-phosphate metabolites are much stronger glycating agents than glucose on a molar basis.68 In keeping with this is the evidence that an ARI has been shown to effect the fluorescence level of endoneurial extracellular matrix from diabetic rats'51 and aminoguanidine, a glycation inhibitor, partially protects against the nerve conduction slowing and nerve fibre damage in chronically diabetic rats.'52 Potentially, excess protein glycation in diabetes could have detrimental effects on the endoneurial DrlS REVIEW microenvironment either by damaging the vascular supply, or by directly altering the composition of the extracellular matrix. Schwann cells and/or regenerating axons interact with extracellular proteins via specific membrane 'substrate adhesion molecules' or 'SAMS' which may also be an important modulation of n e u r o t r o p h i~m . '~~-'~~ This is reflected by the inability of laminin to support neurite outgrowth in tissue culture, after the laminin underwent chemical g 1~c a t i o n . l~~ Therefore the nonenzymatic glycation of extracellular matrix proteins could interfere with their ability to exert neurotrophic effects on peripheral nerve fibres.
Growth Factors
Recent advances in the treatment of drug-induced neuropathies with neurotrophic agents have rekindled interest in neurotrophism and, in particular, the potential role of neurotrophic factors in the pathogenesis and treatment of diabetic neuropathy.
The prototypic neurotrophic agent is NGF, discovered by Levi-Montaicini and H a r n b~r g . '~' NGF is produced by target organs of autonomic and sensory neurons where levels of NGF mRNA parallel the density of innervation by NGF-sensitive neurons.' s7,158 Retrograde transport of NGF from target organs to neuronal cell bodies is required for normal growth, maintenance, and regeneration of the peripheral nervous system. Recently, there is strong evidence suggesting that adult Schwann cells also make growth factors and express growth factor receptors during neuronal development. ' 59,1 6o These growth factors include not only NGF but also ciliary neurotrophic factor (CNTF) and IGF-I.
Potential blunting of normal neurotrophic responses could play a role in the pathogenesis of diabetic neuropathy. Persistent hyperglycaemia may:
1. decrease growth factor synthesis by target organs; 2. disrupt retrograde transport of growth factors to the neuronal cell body; 3. affect the signal transduction mechanism of growth factors in neurons; or 4. alter the ability of neurons or Schwann cells to produce growth factors required for normal cell maintenance.
Current data indicate all four possibilities may contribute, either individually or collectively, to the pathogenesis of diabetic neuropathy.
Growth factor Synthesis by Target Organs
It has been recognized for many years that trophic substances in the nervous system could influence the developmental fate of a neuron. The best studied of these is NGF, a protein produced by target cells of sympathetic and neural-crest derived sensory neurons. After retrograde axonal transport, NGF can induce enzymes required for neurotransmitter synthesis, protein phosphorylation, methylation, and gene expression of ras-like proteins in neurons. NGF is required for normal function of these neurons in embryonic, postnatal, and adult life, and loss of NGF leads to neuronal dysfunction. These same NGF requiring sensory neurons, are commonly affected in diabetes, producing autonomic and/ or sensory neuropathy(s). Evidence suggests that NGF may play a role in the pathophysiology of these neuropathies. Endogenous NGF levels are reduced in sympathetically innervated target organs of streptozotocin-treated rats. 1 6 ' In both streptozotocin-treated rats as well as genetically diabetic mice (C57BL/KsJ db/db), there is a profound decrease of NGF production by the submandibular glands.'62 In humans, patients with diabetic neuropathy have significantly lower levels of serum NGF than non-diabetic controls.163 These data all suggest that growth factor production is altered in diabetes, and such a disruption of normal neurotrophic factor production may play a role in the pathogenesis of diabetic neuropathy.
Axonaf Transport of Growth factors
NGF binds selectively to the terminal proteins of sympathetic and neural crest-derived sensory neurons, and, after internalization, is transported by retrograde axonal flow to the cell bodies. This transport is altered in streptozotocin diabetic rats. Mesenteric nerves, which supply the alimentary tract, can develop a distal diabetic axonopathy. During experimentally induced diabetes, retrograde axonal transport of NGF along the mesenteric nerves to the superior mesenteric ganglion is reduced by approximately half.'64 Similarly, NGF transport is decreased in diabetic somatic sensory n e~r 0 n s . l~~ These alterations in NGF transport form a subset of more widespread transport dysfunction in diabetes. Decreased axonal transport during experimentally induced diabetes has been reported for proteins, gl ycoproteins, and neurotran~mitters.'~~ These results suggest that impairment of axonal transport, especially the retrograde flow of growth factors, may play a role in the pathogenesis of diabetic neuropathy.
Signal Transduction of Growth factors in Diabetes
In neural tissues, activation of muscarinic, cholinergic, adrenergic, histaminergic or serotergic receptors results in stimulation of PI turnover.166 Interestingly, not only have neurotransmitters been linked to PI turnover but NGF has also been shown to stimulate PI turnover in rat superior cervical ganglia'67 and PC12 cells.'68 The most extensively studied growth factor which can be coupled to PI turnover is, however, epidermal growth factor (EGF). When EGF binds to its receptor on the A-431 cell, there is an increase in PI turnover,'69 followed by an increase in intracellular calcium, and PKC mediated REVIEW m phosphorylation of the EGF receptor. ' 70 Recently, IGF-II has been shown to stimulate IP, and DAG production in proximal tubular basolateral membranes from canine kidney;' 71 mannose-6-phosphate may potentiate this s t i r n u l a t i~n , '~~ reflecting a potential role for carbohydrate moieties in the regulation of growth factor signal transduction.
Although alterations in PI metabolism are well documented in diabetes, much less is known about the potential role growth factors may play in these alterations. The definitive experiments, examining growth factor coupled PI turnover in multiple diabetic tissues, have not been done.
Growth Factor Production
In adult rat sciatic nerve, NGF production is low, as long as axonal contact is maintained.'73,'74 W' ith nerve transection, Schwann cells distal to the cut, including those which ensheath motor axons, dramatically increase their production of NGF'75 and NGF receptor^,'^^,'^^ reaching a maximal at 5 to 7 days. Transection of selective ventral roots entering the sciatic nerve results in increased NGF receptor expression by Schwann cells associated with degenerating motor neurons alone, but not intact sensory n e~r 0 n s . l~~ Analogous to axonal regeneration, Schwann cells express NGF receptors during normal development with a dramatic decline in receptor number (25-fold) upon PNS maturation.'60 Schwann cells have also been implicated as local producers of CNTF and IGF-I. Motor neurons serve as the major target for CNTF, a small polypeptide originally purified from chick and rabbit sciatic nerve.178 CNTF enhances avian motor neuron survival both in vivo and in vitro and can rescue neonatal rat facial motor neurons from experimentally induced cell death.'79,180 IGF-I immunoreactivity is present in Schwann cell cytoplasm and is increased by sciatic nerve transection.18' Addition of IGF-I to freeze injured sciatic nerves enhances regeneration in a dose-dependent fashion.'82 In streptozotocin-treated rats, there is a decrease in serum IGF-I level^'^^-'^^ and a reduction in IGF-I mRNA in liver, kidney, lung, and
The effects of diabetes on nervous system expression of NGF, IGF-I or CNTF remains however unknown. Successful axonal maintenance, regeneration, and reformation of axon-Schwann cell contacts is likely to be dependent on this local synthesis of growth factors and growth factor receptors. ' 7 3 Blunted neurotrophic effects may occur in diabetes and contribute to the pathogenesis of diabetic neuropathy. Currently, these ideas remain untested and further work in this field is required.
Concluding Remarks
In summary, all of the above abnormalities identified in diabetes, can be traced to the metabolic effects of hyperglycaernia and/or other effects of insulin deficiency on the richly varied cell constituents of peripheral nerve, its supporting connective tissue and vascular elements, and possibly the autonomic innervation that controls the endoneurial blood flow. Considerable evidence appears to link both the metabolic and vascular hypotheses of diabetic neuropathy. For example, increased glucose flux through the polyol pathway may be deleterious in diabetes by precipitating osmotic dysregulation in tissue with high levels of AR2 activity when myo-inositol and taurine depletion may become rate limiting for their normal metabolic functions; producing redox perturbations manifest as oxidation and reduction of the NADPH/NADP+ and NADH/NAD+ redox couples, respectively, and increasing nonenzymatic protein glycation.These metabolic perturbations may potentially lead to alterations in nerve blood flow due to disruption of sympathetic tone and disturbances in the production of vascoactive factors. Alterations in fatty acid metabolism in diabetes may directly disrupt nerve structure and function but also may disturb the production of vasodilating eicosanoids. In addition, accumulating evidence implicates a role for blunted neurotrophism in the development of diabetic neuropathy.
Although the diverse effects of hyperglycaemia, at first glance, appear to preclude the development of an effective therapeutic strategy in the management of this chronic complication, the interdependence of the many factors which are necessary for normal nerve function suggests that selective intervention aimed at a key defect early in this cascade may correct many of the later defects as has been observed by the wide ranging effects of the ARls.
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